Preclinical data presented for the first time demonstrated successful manufacture and functional activity of KYV-101 in the blood of patients with systemic lupus erythematosus (SLE), commonly known as lupus KYV-101 is a novel, fully human CD19 CAR T-cell therapy for use in B cell-driven…
